FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4291017675> ?p ?o ?g. }

• W4291017675 abstract "To investigate the efficacy and safety of docetaxel chemotherapy combined with androgen-deprivation therapy for patients with high-volume disease metastatic hormone-sensitive prostate cancer.153 cases of high-volume disease metastatic hormone-sensitive prostate cancer in Minhang Hospital between January 2018 and December 2019 were analyzed retrospectively, including the number of patients, age, initial PSA level, Gleason score, TNM stage and ECOG score. 90 patients in the endocrine therapy group received continuous ADT, and 63 patients in the combined chemotherapy group received docetaxel plus ADT. The progression-free survival time (time from initiation of prostate cancer treatment to progression to CRPC), PSA response rate, and adverse reactions were compared between the two groups.All 153 cases were closely followed up for a period of 12.3-35.3 months, with a median follow-up time of 23.5 months. The median time to reach the lowest point of PSA in the two groups was 6.3 months and 7.9 months (P = 0.018) in the combination chemotherapy group and the ADT group alone, with 27 (42.9%) and 12 (13.3%) cases in the two groups Within 12 months of treatment, PSA decreased to below 0.2 ng/ml (P = 0.02), and progression-free survival was 16.9 months (6.5-28.5 months) and 11.2 months (4.3-22.7 months) in the two groups. (P < 0.001). There were 18 cases (28.6%) and 54 cases (60%) in the two groups with disease progression (P < 0.001). There were 6 cases (9.5%) and 15 cases (16.7%) in the combination chemotherapy group and the ADT group died of prostate cancer and related complications, respectively. All 63 cases in the combined chemotherapy group completed 6 cycles of chemotherapy. 39 (61.9%) cases experienced varying degrees of neutropenia, of which 12 (19%) experienced grade 3-4 neutropenia, with 6 cases (9.5%) developed febrile neutropenia. 30 cases (47.6%) had toxic reactions in the digestive system, and 3 case (4.3%) had grade 3 liver dysfunction. 27 cases (42.8%) had skin and mucosal toxicity. 9 cases (14.3%) had mild fluid retention. No blood and digestive toxicity were observed in the ADT group. 33 cases (52.4%) and 48 (53.3%) of the two groups had symptoms of afternoon hot flashes and fatigue, (P = 0.961).Docetaxel chemotherapy combined with endocrine therapy could be one of effective treatments for delaying castration resistance of HVD-mHSPC, which could prolong PFS effectively and obtain a higher PSA response rate, high safety under close monitoring, and controllable adverse reactions." @default.
• W4291017675 created "2022-08-13" @default.
• W4291017675 creator A5002884701 @default.
• W4291017675 creator A5042838402 @default.
• W4291017675 creator A5075222850 @default.
• W4291017675 creator A5082905275 @default.
• W4291017675 creator A5085752715 @default.
• W4291017675 creator A5086414772 @default.
• W4291017675 creator A5089366118 @default.
• W4291017675 date "2022-08-11" @default.
• W4291017675 modified "2023-09-30" @default.
• W4291017675 title "Docetaxel chemotherapy plus androgen-deprivation therapy in high-volume disease metastatic hormone-sensitive prostate cancer in Chinese patients: an efficacy and safety analysis" @default.
• W4291017675 cites W1972298018 @default.
• W4291017675 cites W2067103679 @default.
• W4291017675 cites W2107464496 @default.
• W4291017675 cites W2142466432 @default.
• W4291017675 cites W2150865892 @default.
• W4291017675 cites W2178183066 @default.
• W4291017675 cites W2214621962 @default.
• W4291017675 cites W2272984102 @default.
• W4291017675 cites W2754672431 @default.
• W4291017675 cites W2777183039 @default.
• W4291017675 cites W2787804990 @default.
• W4291017675 cites W2947815897 @default.
• W4291017675 cites W3095258112 @default.
• W4291017675 cites W3128646645 @default.
• W4291017675 cites W4211087830 @default.
• W4291017675 doi "https://doi.org/10.1186/s40001-022-00773-1" @default.
• W4291017675 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35953852" @default.
• W4291017675 hasPublicationYear "2022" @default.
• W4291017675 type Work @default.
• W4291017675 citedByCount "1" @default.
• W4291017675 countsByYear W42910176752023 @default.
• W4291017675 crossrefType "journal-article" @default.
• W4291017675 hasAuthorship W4291017675A5002884701 @default.
• W4291017675 hasAuthorship W4291017675A5042838402 @default.
• W4291017675 hasAuthorship W4291017675A5075222850 @default.
• W4291017675 hasAuthorship W4291017675A5082905275 @default.
• W4291017675 hasAuthorship W4291017675A5085752715 @default.
• W4291017675 hasAuthorship W4291017675A5086414772 @default.
• W4291017675 hasAuthorship W4291017675A5089366118 @default.
• W4291017675 hasBestOaLocation W42910176751 @default.
• W4291017675 hasConcept C121608353 @default.
• W4291017675 hasConcept C126322002 @default.
• W4291017675 hasConcept C126894567 @default.
• W4291017675 hasConcept C143998085 @default.
• W4291017675 hasConcept C197934379 @default.
• W4291017675 hasConcept C2776694085 @default.
• W4291017675 hasConcept C2777899217 @default.
• W4291017675 hasConcept C2780192828 @default.
• W4291017675 hasConcept C2781190966 @default.
• W4291017675 hasConcept C2781406297 @default.
• W4291017675 hasConcept C71924100 @default.
• W4291017675 hasConceptScore W4291017675C121608353 @default.
• W4291017675 hasConceptScore W4291017675C126322002 @default.
• W4291017675 hasConceptScore W4291017675C126894567 @default.
• W4291017675 hasConceptScore W4291017675C143998085 @default.
• W4291017675 hasConceptScore W4291017675C197934379 @default.
• W4291017675 hasConceptScore W4291017675C2776694085 @default.
• W4291017675 hasConceptScore W4291017675C2777899217 @default.
• W4291017675 hasConceptScore W4291017675C2780192828 @default.
• W4291017675 hasConceptScore W4291017675C2781190966 @default.
• W4291017675 hasConceptScore W4291017675C2781406297 @default.
• W4291017675 hasConceptScore W4291017675C71924100 @default.
• W4291017675 hasIssue "1" @default.
• W4291017675 hasLocation W42910176751 @default.
• W4291017675 hasLocation W42910176752 @default.
• W4291017675 hasLocation W42910176753 @default.
• W4291017675 hasLocation W42910176754 @default.
• W4291017675 hasOpenAccess W4291017675 @default.
• W4291017675 hasPrimaryLocation W42910176751 @default.
• W4291017675 hasRelatedWork W2060708716 @default.
• W4291017675 hasRelatedWork W2402249956 @default.
• W4291017675 hasRelatedWork W2403920140 @default.
• W4291017675 hasRelatedWork W2588988563 @default.
• W4291017675 hasRelatedWork W2770702948 @default.
• W4291017675 hasRelatedWork W2776356588 @default.
• W4291017675 hasRelatedWork W2890184401 @default.
• W4291017675 hasRelatedWork W3089313947 @default.
• W4291017675 hasRelatedWork W3132581442 @default.
• W4291017675 hasRelatedWork W785005902 @default.
• W4291017675 hasVolume "27" @default.
• W4291017675 isParatext "false" @default.
• W4291017675 isRetracted "false" @default.
• W4291017675 workType "article" @default.